Aachen, Germany

Saskia Zemolka

USPTO Granted Patents = 12 


 

Average Co-Inventor Count = 6.5

ph-index = 5

Forward Citations = 72(Granted Patents)


Location History:

  • Constance, DE (2010)
  • Aachen, DE (2008 - 2013)

Company Filing History:


Years Active: 2008-2013

Loading Chart...
Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Saskia Zemolka

Introduction

Saskia Zemolka is a prominent inventor based in Aachen, Germany. She has made significant contributions to the field of pharmaceuticals, holding a total of 12 patents. Her work focuses on developing novel compounds that have potential therapeutic applications.

Latest Patents

Among her latest patents are the spirocyclic cyclohexane compounds, which are designed for the treatment and inhibition of pain and other conditions mediated by the ORL-1 or the μ-opioid receptor. These compounds are characterized by specific structural formulas, where R, R', R'', and X have defined meanings. Additionally, she has developed spirocyclic azaindole derivatives, which include substituted azaindole derivatives and methods for their production. These derivatives are intended for use in medicaments, showcasing her commitment to advancing medical science.

Career Highlights

Saskia has worked with notable companies such as Grünenthal GmbH, where she has contributed her expertise in pharmaceutical innovation. Her career is marked by a dedication to research and development, leading to the creation of impactful medicinal compounds.

Collaborations

Throughout her career, Saskia has collaborated with esteemed colleagues, including Werner Guenter Englberger and Klaus Linz. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Saskia Zemolka's contributions to the field of pharmaceuticals through her innovative patents and collaborations highlight her role as a leading inventor. Her work continues to influence the development of new therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…